To hear about similar clinical trials, please enter your email below
Trial Title:
Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment
NCT ID:
NCT05858203
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
ATAC-seq and ChIP-seq
Description:
CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected
to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand
the involvment of Che-1 in MM tumorogenesis.
Summary:
Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of
proliferating antibody producing plasma cells in the bone marrow. In the last few years
many studies have emphasized the biological complexity and heterogeneity of MM as a
result of both genetic and epigenetic aberrations. Che-1/AATF (Che-1) is a
transcriptional cofactor involved in cell cycle regulation, apoptosis, DNA damage and
stress response. it can be hypothesized that Che-1 might contribute to the establishment
of the MM malignant phenotype by sustaining global transcription through its ability to
modulate chromatin accessibility.
The prospective study on MM human samples aims to understand the involvement of Che-1 in
the transcriptional regulation and chromatin remodeling during the pathology. To this
goal the main objectives are:
- Characterization of Che-1's role in chromatin remodeling and global gene expression
- Study in vivo and in vitro of Che-1 involvement in MM tumorigenesis
- Evaluation of Che-1 as a possible therapeutic target
Criteria for eligibility:
Study pop:
MM Patients
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- MM Patients
Exclusion Criteria:
- No exclusion criteria
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Regina elena Cancer Institute
Address:
City:
Roma
Zip:
00144
Country:
Italy
Status:
Active, not recruiting
Facility:
Name:
"Regina Elena" National Cancer Institute
Address:
City:
Rome
Zip:
00144
Country:
Italy
Status:
Recruiting
Start date:
December 22, 2020
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Regina Elena Cancer Institute
Agency class:
Other
Source:
Regina Elena Cancer Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05858203
